Pneumonia vaccine study for lung cancer patients
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how the pneumonia vaccine (which protects against a common cause of pneumonia) affects people with lung cancer. By joining, you'll help researchers understand if this vaccine can improve outcomes for lung cancer patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a lung cancer diagnosis (any type or stage).
- You must never have received a pneumonia vaccine (pneumococcal vaccine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing how well the COVID-19 vaccine works for people with lung cancer to prevent another infection. It also looks at certain biomarkers in your blood that might help predict your body's immune response.
This trial studies how well the pneumonia vaccine works in people with esophageal or liver cancer who have low white blood cell counts after chemoradiation. It aims to see if the vaccine can still protect them from infection.
This trial tests whether a pneumococcal vaccine can help protect against a specific type of pneumonia bacteria. Researchers want to see if the vaccine can create antibodies that work against multiple strains.
This study tests a pneumococcal vaccine designed for 20 types of bacteria in older adults who are hospitalized with suspected community-acquired pneumonia. It aims to see how the vaccine works in real-world care and whether it affects how pneumonia happens or progresses.
This Phase 2 study tests a specific plan for giving a pneumococcal vaccine in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It may help improve protection against pneumococcal infections in patients who have not started CLL/SLL treatment yet.
This trial tests a series of two pneumococcal vaccines (PCV20 and PPSV23) in people with CLL-related immune weakness. It aims to see how well the vaccines work and how safe they are for preventing serious lung infections.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.